These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29052559)

  • 1. Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study.
    Zheng Y; Cai GY; He LQ; Lin HL; Cheng XH; Wang NS; Jian GH; Liu XS; Liu YN; Ni ZH; Fang JA; Ding HL; Guo W; He YN; Wang LH; Wang YP; Yang HT; Ye ZM; Yu RH; Zhao LJ; Zhou WH; Li WG; Mao HJ; Zhan YL; Hu Z; Yao C; Wei RB; Chen XM
    Chin Med J (Engl); 2017 Oct; 130(20):2402-2409. PubMed ID: 29052559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study.
    Zheng Y; Wang NS; Liu YN; He LQ; Jian GH; Liu XS; Ni ZH; Cheng XH; Lin HL; Zhou WH; Wang YP; Fang JA; He YN; Yang HT; Zhao LJ; Ding HL; Wang LH; Yu RH; Li WG; Ye ZM; Guo W; Zhan YL; Mao HJ; Hu Z; Yao C; Cai GY; Chen XM
    Chin J Integr Med; 2019 Mar; 25(3):168-174. PubMed ID: 30467695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
    Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Yiqi Peiyuan granules for improving the short-term prognosis of patients with acute kidney injury: A multicenter, double-blind, placebo-controlled, randomized trial.
    Wu JJ; Zhang TY; Qi YH; Zhu MY; Fang Y; Qi CJ; Cao LO; Lu JF; Lu BH; Tang LM; Shen JX; Mou S
    J Integr Med; 2024 May; 22(3):279-285. PubMed ID: 38688809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
    Zhang L; Li P; Xing CY; Zhao JY; He YN; Wang JQ; Wu XF; Liu ZS; Zhang AP; Lin HL; Ding XQ; Yin AP; Yuan FH; Fu P; Hao L; Miao LN; Xie RJ; Wang R; Zhou CH; Guan GJ; Hu Z; Lin S; Chang M; Zhang M; He LQ; Mei CL; Wang L; Chen X
    Am J Kidney Dis; 2014 Jul; 64(1):57-65. PubMed ID: 24631042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficiency of benazepril combined with wind dispelling and dampness removing chinese herbs on stage 3 chronic kidney disease with wind-dampness syndrome: a prospective study].
    Fang YQ; Lu Y; Wang YJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Mar; 32(3):311-6. PubMed ID: 22686073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes: A Randomized, Double-blind, Multicenter Clinical Trial.
    Wang X; Hu D; Dang S; Huang H; Huang CX; Yuan MJ; Tang YH; Zheng QS; Yin F; Zhang S; Zhang BL; Gao RL;
    Chin Med J (Engl); 2017 Jul; 130(14):1639-1647. PubMed ID: 28685712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
    Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
    Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
    Yan M; Wen Y; Yang L; Wu X; Lu X; Zhang B; Huang W; Li P
    Trials; 2016 May; 17(1):259. PubMed ID: 27216240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.
    Wu J; Duan SW; Sun XF; Li WG; Wang YP; Liu WH; Zhang JR; Lun LD; Li XM; Zhou CH; Li JJ; Liu SW; Xie YS; Cai GY; Ma L; Huang W; Wu H; Jia Q; Chen XM
    Chin Med J (Engl); 2016 Aug; 129(16):1894-903. PubMed ID: 27503012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
    Wu R; Wei F; Qu L; Bai L; Li J; Li F; Yan W; Wang Q; Wei J
    Trials; 2020 Nov; 21(1):951. PubMed ID: 33228726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial.
    Wang YJ; He LQ; Sun W; Lu Y; Wang XQ; Zhang PQ; Wei LB; Cao SL; Yang NZ; Ma HZ; Gao J; Li P; Tao XJ; Yuan FH; Li J; Yao C; Liu X
    J Ethnopharmacol; 2012 Feb; 139(3):757-64. PubMed ID: 22178174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.
    Li P; Chen Y; Liu J; Hong J; Deng Y; Yang F; Jin X; Gao J; Li J; Fang H; Liu G; Shi L; Du J; Li Y; Yan M; Wen Y; Yang W
    PLoS One; 2015; 10(5):e0126027. PubMed ID: 25938778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of traditional Chinese herbal medicine in patients with diabetic kidney disease: study protocol for a randomized controlled trial.
    Wang M; Wang Z; Zhou J; Sun W; Wang Y; Han M; Yang H; Liu WJ; Wang Y
    Trials; 2018 Jul; 19(1):389. PubMed ID: 30016983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial.
    Li S; Rao XR; Dai XW; Pei K; Wang L; Huo BM; Wang XJ; Kong LX; Zhang NN; Lian FM
    Medicine (Baltimore); 2017 Jul; 96(28):e7448. PubMed ID: 28700482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
    Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease: Protocol of a double-blinded, randomized, controlled trial.
    Hu X; Wang J; Yang H; Ji S; Li Y; Xu B; Cui H
    Medicine (Baltimore); 2021 May; 100(20):e25759. PubMed ID: 34011035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
    Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
    Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.